Trump’s drug pricing order boosts case for generics and biosimilars: Kiran Mazumdar-Shaw
- Posted on May 13, 2025
- By Financial Express
- 2 Views
Trump’s drug pricing order boosts case for generics and biosimilars: Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong Q4 generics growth driven by new launches, biosimilars performance, and the company's future growth strategy focused on scaling and innovation.
